← TrialMatch
HomeTrials

Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resec

Based on the unique patented MONOD and Methyl Titan methylation sequencing technology on lung cancer tissue and blood samples, a lung cancer MRD monitoring panel is designed. The panel is used to detect molecular residual disease of stage IB-IIIB non-small cell lung cancer patients underwent radical surgery, explore pe

Condition(s)Non-small Cell Lung Cancer
StatusRecruiting
Study typeObservational
SummaryBased on the unique patented MONOD and Methyl Titan methylation sequencing technology on lung cancer tissue and blood samples, a lung cancer MRD monitoring panel is designed. The panel is used to detect molecular residual disease of stage IB-IIIB non-small cell lung cancer patients underwent radical surgery, explore personalized analysis models, and conduct research on recurrence monitoring for non-small cell lung cancer patients.
Who can participateInclusion Criteria: 1. Age ≥ 18 years old, regardless of gender; 2. Patients with pathological diagnosis of non-small cell lung cancer and clinical staging of stage IB-IIIB; 3. Able to undergo radical surgical treatment; 4. Physical condition score (ECOG) ≤1; 5. The expected survival time exceeds 24 months; 6. Volunteer to participate in this study and sign an informed consent form. Exclusion Criteria: 1. Individuals with a history of other malignant tumors within 5 years; 2. Those who have undergone neoadjuvant therapy before surgery; 3. Postoperative incision margin R1 or incision margin R2; 4. Those who have undergone a blood transfusion within 2 weeks before the surgery; 5. Individuals with systemic inflammatory response syndrome; 6. Those with serious diseases of important organs such
Ages18 Years
SexAll
Lead sponsorShanghai Pulmonary Hospital, Shanghai, China
LocationsShanghai, Shanghai Municipality, China
Start date2023-10-25
NCT IDNCT05965024
Official listinghttps://clinicaltrials.gov/study/NCT05965024

🔍 Search all trials →